Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...

Falls and other non-dopaminergic symptoms in Parkinson’s disease remain a significant unmet need, with limited effective ...

Structure Therapeutics' Phase 2 data for Aleniglipron show 16% weight loss at 44 weeks with strong tolerability and no safety ...

Get ready for your aha moment: Every weekday, host Meghna Chakrabarti pierces your news bubble to expose the whole story. Getting answers to the questions that need to be asked, examining our history ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.